Business Wire

CA-CROWN-BIOSCIENCE

27.10.2020 13:02:08 CET | Business Wire | Press release

Share
Crown Bioscience Increases APAC Capacity with New Facility in Zhongshan, China

Crown Bioscience, a JSR Life Sciences company, today announces the opening of a new oncology-focused research facility in Zhongshan, China to satisfy increased customer demand.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027005098/en/

In addition to the Company’s four facilities across the US and Europe, CrownBio’s existing APAC footprint currently includes three sites located in Beijing, Taicang, and Suzhou, as well as one in Taiwan. Once completed, this new building will add more than 2,000m2 of new vivarium space to support CrownBio’s in vivo oncology platforms, helping satisfy predicted near-term growth.

CrownBio’s world-leading products and services are used by pharmaceutical and biotech customers across APAC, North America, and Europe to accelerate and de-risk their drug discovery programs. With the significant and continued growth of CrownBio’s client base, the Zhongshan facility has been purpose built to meet expanding study needs.

The research and drug development facility features BSL-2 laboratories and will include a state-of-the-art ABSL-2 vivarium. Initial capabilities will focus on expanding cell line-derived xenograft model availability and study throughput, with an increased roster of cutting edge, translational oncology models becoming available. Full operational capacity is expected in early 2021.

“The establishment of our new Zhongshan facility demonstrates our continued commitment to our clients, to provide sustained rapid study initiation combined with robust cost-effectiveness,” said John Gu, chief operating officer at CrownBio. “Through our growth, we can more fully support our clients in their goals of more rapid and efficient cancer drug development”.

A site opening event and ribbon cutting ceremony will take place on October 30th 2020.

About Crown Bioscience Inc.

Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit:

● https://www.crownbio.com

● https://www.jsrlifesciences.com

Social Media:

https://www.facebook.com/crownbio/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hitachi Unveils a New Global Digital Services Company Turning Cloud, Data and AI Into Measurable Business Outcomes: Hitachi Digital28.10.2026 01:00:00 CET | Press release

Uniting GlobalLogic and Hitachi Digital Services under a single global brand, Hitachi Digital will deliver end-to-end capabilities that help organizations in complex, mission-critical industries drive business transformation Hitachi, Ltd. (TSE:6501, “Hitachi”) today announced plans to launch Hitachi Digital Inc. (“Hitachi Digital”), a new global digital services company, on April 1, 2027, in accordance with the integration plan announced in January 20261. Hitachi Digital will unite Hitachi’s U.S. subsidiaries, GlobalLogic Inc. (“GlobalLogic”) and Hitachi Digital Services LLC (“Hitachi Digital Services”) under a single company using the Hitachi brand, with a brand campaign launching today. Hitachi Digital will steadily guide enterprise digital transformation at the convergence of cloud, data and AI toward concrete business results. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027531796/en/ Hitachi unveils a new global di

Logitech Announces Q2 Fiscal Year 2027 Results27.10.2026 21:05:00 CET | Press release

Second Quarter Marks Company’s Eleventh Consecutive Quarter of Growth SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the second quarter of Fiscal Year 2027. Sales were $1.22 billion, up 3 percent in US dollars and 2 percent in constant currency, compared to Q2 of the prior year. GAAP gross margin was 44.9 percent, up 150 basis points compared to Q2 of the prior year. Non-GAAP gross margin was 45.2 percent, up 140 basis points compared to Q2 of the prior year. GAAP operating income was $201 million, up 5 percent compared to Q2 of the prior year. Non-GAAP operating income was $231 million, up 0.4 percent compared to Q2 of the prior year. GAAP earnings per share (EPS) was $1.25, up 9 percent compared to Q2 of the prior year. Non-GAAP EPS was $1.51, up 4 percent compared to Q2 of the prior year. Cash flow from operations was $164 million. The quarter-ending cash balance was $1.51 billio

Grid Dynamics Launches Business Process Consulting Practice to Bridge the Gap Between AI Investment and Business Results27.10.2026 21:05:00 CET | Press release

Key Takeaways: Grid Dynamics expands its enterprise AI transformation capabilities with a new Business Process Consulting practice enabling end-to-end AI transformation for Fortune 1000 enterprises. Integrated with Grid Dynamics' established AI engineering expertise, the practice helps enterprises identify business opportunities, provides investment justification to technology implementation and measurable value realization by enterprise-wide change management. The practice combines Grid Dynamics' ARC (Assess, Reengineer, Capture) methodology with a technology-driven approach to consulting, incorporating advanced AI capabilities into business process optimization and personalized, AI-powered change management. Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”), a premier AI transformation partner for the Fortune 1000, today announced the launch of its Business Process Consulting practice, extending the company's AI transformation capabilities across the entire AI adoption li

Hightouch Partners with Independent Media to Activate Reader and Commercial Data27.10.2026 17:01:00 CET | Press release

The partnership will help Independent Media deliver more relevant reader engagement, build premium advertising audiences, and support affiliate and e-commerce growth. Hightouch, the leading agentic marketing platform, today announced a partnership with Independent Media, publisher of The Independent. Independent Media will use Hightouch to connect its customer data to marketing tools. With Hightouch, the company will send readers more relevant membership and subscription offers, build stronger audiences for its advertising partners, and grow its affiliate and e-commerce business. “Deepening customer relationships and delivering real value to our commercial partners requires moving seamlessly from insight to action,” said Krishan Gandhi, Director of Data Intelligence and Monetisation at Independent Media. “Partnering with Hightouch allows us to utilise our warehouse data directly into our engagement tools, powering real-time, omnichannel journey orchestration, while enabling us to build

IFF Identifies Ten Consumer Moments Reshaping Food and Beverage Innovation in the GLP-1 Era27.10.2026 16:00:00 CET | Press release

New research reveals how smaller, more intentional eating occasions are creating new opportunities for nutrition, flavor and renewed enjoyment. IFF (NYSE: IFF)—a global leader in flavors, fragrances and health and biosciences, today launched its latest report, “GLP-1 Consumer Moments of Opportunity.” The report uncovers ten emerging consumer moments that reflect the changing needs of consumers using GLP-1 medications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026614988/en/ New report from IFF uncovers ten emerging consumer moments that reflect the changing needs of consumers using GLP-1 medications. “What GLP-1 users need from food and beverage products depends on the moment, and those needs can change many times throughout the day,” said Yuvraj Arora, president of IFF Taste. “The most successful innovations will be designed around the occasions that matter most to consumers, delivering the right balance of nutrition

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye